Delusions: Clinical Trials

6 trials for Delusions, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 6 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 6
Phase 31Completed 1

Follow Delusions: new trials by email Literature Review of Delusions trials Research Report on Delusions

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment of Psychosis and Agitation in Alzheimer's Disease
Lithium, Placebo - Alzheimer's Disease, Psychosis
Phase 2CompletedNew York State Psychiatric Institute772014-06-012024-05-02
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses) - Schizophrenia Disorders
Phase 2CompletedNovartis Pharmaceuticals572010-05-012020-12-24
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
t-VNS verum, t-VNS placebo - Schizophrenia
Phase 2Completedcerbomed GmbH202010-03-012012-09-12
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
ACP-103 - Schizophrenia
Phase 2CompletedACADIA Pharmaceuticals Inc.4002005-08-012007-03-22
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
Ethyl-eicosapentaenoic acid (EPA), Vitamins E + C, Etyl EPA (placebo) - Schizophrenia, Schizophreniform Disorders
Phase 2 / Phase 3CompletedUniversity Hospital, Aker992001-09-012011-01-04
Treating Behavioral Disturbances in Individuals With Dementia
Citalopram, Risperidone - Dementia
Phase 2CompletedUniversity of Pittsburgh1372000-01-012014-03-10

Narrower conditions

Hallucinations (5)  ·  Psychotic Disorders (4)  ·  Schizophrenia (4)  ·  Aggression (2)  ·  Alzheimer Disease (2)  ·  Dementia (2)  ·  Mental Disorders (2)  ·  Cognition Disorders (1)  ·  Hypertriglyceridemia (1)  ·  Illusions (1)  ·  Neuroleptic Malignant Syndrome (1)  ·  Paranoid Behavior (1)  ·  Psychomotor Agitation (1)  ·  Schizophrenia, Catatonic (1)

Broader conditions

Behavior (6)  ·  Behavioral Symptoms (6)  ·  Nervous System Diseases (6)  ·  Neurobehavioral Manifestations (5)  ·  Neurologic Manifestations (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Perceptual Disorders (5)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (5)  ·  Signs and Symptoms (5)  ·  Mental Disorders (4)  ·  Neurocognitive Disorders (4)  ·  Brain Diseases (3)  ·  Central Nervous System Diseases (3)  ·  Aberrant Motor Behavior in Dementia (2)  ·  Dyskinesias (2)

Interventions

3-(6-p-tolylpyridin-3-yloxy)-1-azabicyclo(2.2.2)octane (1)  ·  Citalopram (1)  ·  Lithium (1)  ·  Lithium Carbonate (1)  ·  Risperidone (1)  ·  Single Person (1)  ·  eicosapentaenoic acid ethyl ester (1)  ·  pimavanserin (1)

Sponsors

ACADIA Pharmaceuticals Inc. (1)  ·  New York State Psychiatric Institute (1)  ·  Novartis Pharmaceuticals (1)  ·  University Hospital, Aker (1)  ·  University of Pittsburgh (1)  ·  cerbomed GmbH (1)

Countries

United States (4)  ·  Brazil (1)  ·  Germany (1)  ·  Norway (1)

Top investigators

Bruce G. Pollock, MD, PhD (1)  ·  DP Devanand, MD (1)  ·  Daniel van Kammen, MD, PhD (1)

Results publications

PMID 20625270, PMID 29859917, PMID 34059401, PMID 37732619

NIH funding

R01AG047146 (1), R01MH059666 (1)